GleamWall
中文EN

SRZN Surrozen, Inc./DE

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1824893 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY192.1%
TTM net income YoY-349.0%
TTM EPS YoY-138.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-485.4%
Net margin-3,706.4%
FCF margin-292.3%
EBITDA margin-483.4%

Returns

ROE—
ROA-384.3%
ROIC (approx.)—
Asset turnover0.10x

Leverage & solvency

Liabilities / assets407.8%
Debt / equity—
Current ratio7.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.08x
Accruals ratio-354.2%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$5.00M$5.00M$528,000$983,000$983,000$983,000$655,000
R&D expense$10.84M$8.48M$9.33M$8.99M$7.77M$6.04M$6.56M$5.35M
SG&A expense$6.80M$6.89M$6.13M$4.18M$4.09M$3.96M$3.98M$3.90M
Operating income-$17.64M-$10.37M-$10.46M-$12.64M-$10.88M-$9.02M-$9.55M-$8.59M
Income tax$0$0$0$0$0$0$0—
Net income-$129.72M$50.18M-$127.50M-$183.16M-$71.64M$39.75M-$26.97M-$28.04M
EBITDA-$17.59M-$10.32M-$10.39M-$12.59M-$10.82M-$8.88M-$9.26M-$8.27M
EPS (basic)-11.022.75-11.65—-8.362.55-7.43—
EPS (diluted)-11.02-0.41-11.65—-8.362.55-7.43—
Weighted avg. shares (diluted)11,77423.15M10,949—8,5718.54M3,628—
Balance sheet
Cash & equivalents$100.35M$102.04M$106.91M$89.25M$81.33M$90.39M$101.64M$35.25M
Receivables—$5.00M$5.00M$0$2.32M$2.32M$2.13M$2.04M
Current assets$102.89M$109.40M$113.95M$91.56M$85.86M$94.23M$106.01M$38.93M
PP&E, net$432,000$456,000$488,000$433,000$139,000$176,000$295,000$562,000
Total assets$109.03M$115.61M$120.71M$98.73M$94.05M$102.70M$114.83M$48.47M
Current liabilities$13.61M$9.01M$9.56M$9.93M$6.53M$5.74M$10.58M$7.32M
Total liabilities$444.66M$334.27M$398.86M$286.49M$117.56M$55.58M$109.16M$69.85M
Shareholders' equity-$335.62M-$218.66M-$278.15M-$187.76M-$23.52M$47.11M$5.67M-$21.38M
Shares outstanding12.03M11.75M11.49M9.78M8.57M8.57M8.49M3.26M
Cash flow statement
Operating cash flow-$4.83M-$7.42M-$12.49M-$5.81M-$9.04M-$6.11M-$9.28M$3.48M
Capital expenditure$27,000$19,000$120,000$59,000$24,000$18,000$27,000$19,000
Free cash flow-$4.86M-$7.43M-$12.62M-$5.87M-$9.06M-$6.13M-$9.31M$3.46M
Investing cash flow-$27,000-$19,000-$120,000-$59,000-$24,000-$18,000-$27,000-$19,000
Financing cash flow$3.17M$2.51M$30.28M$13.78M$9,000-$5.12M$76.39M$91,000
Depreciation & amortization$51,000$51,000$65,000$45,000$61,000$137,000$294,000$322,000
Stock-based compensation$2.93M$2.89M$2.10M$1.00M$1.00M$994,000$834,000$900,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.